Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.57 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265714 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL10159392 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL19537371 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL19534525 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12621455 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12658368 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL23880678 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL12939575 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL474592 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL14853791 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4SLC29A1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | MERCK SHARP & DOHME CORP. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | IDENIX PHARMACEUTICALS LLC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-2984097-B1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9447132-B2 | Highly active nucleoside derivative for the treatment of HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447132-B2 | Highly active nucleoside derivative for the treatment of HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014169278-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | P2RY2 315/4885P2RY4 249/4885SLC29A1 51/4885 |
| US-20140309189-A1 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV | SLC28A1, SLC28A2, NUDT1 | P2RY2 1406/4885P2RY4 811/4885SLC29A1 4/4885 |
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | PNP, NUDT1, NUDT14 | P2RY2 1067/4885P2RY4 581/4885SLC29A1 5/4885 |
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | PNP, NUDT1, NUDT14 | P2RY2 1067/4885P2RY4 581/4885SLC29A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.